Phocas Financial Corp. Travere Therapeutics, Inc. Transaction History

Phocas Financial Corp.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 12, 2023	SELL	$15.3 - $22.61 $16,524 - $24,418	-1,080 Reduced 0.48%	223,183 $3.43 Million
Q1 2023 Apr 13, 2023	BUY	$17.82 - $22.89 $1.89 Million - $2.43 Million	106,015 Added 89.65%	224,263 $5.04 Million
Q4 2022 Jan 10, 2023	SELL	$18.47 - $26.14 $2,271 - $3,215	-123 Reduced 0.1%	118,248 $0
Q3 2022 Oct 14, 2022	BUY	$22.91 - $28.63 $2.71 Million - $3.39 Million	118,371 New	118,371 $2.92 Million

196

84.9M

776K

900K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.3B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Phocas Financial Corp., based on Form 13F filings with the SEC.

Stay updated on Phocas Financial Corp. with notifications on news.